Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

Description

The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity \[Pediatric RISE\]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes. Participants will be randomized to receive one of the following for 6-months: * Usual supportive care alone or * Usual supportive care plus Pediatric RISE

Conditions

Neuroblastoma, High-risk Neuroblastoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity \[Pediatric RISE\]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes. Participants will be randomized to receive one of the following for 6-months: * Usual supportive care alone or * Usual supportive care plus Pediatric RISE

A Randomized Phase II Trial Evaluation of the Addition of the Resource Intervention to Support Equity (RISE) to Usual Supportive Care for Children With Newly Diagnosed High-Risk Neuroblastoma

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

Condition
Neuroblastoma
Intervention / Treatment

-

Contacts and Locations

Boston

Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 03079

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patient newly diagnosed with high-risk neuroblastoma
  • * Patient has established care at study site and initiated cancer-directed therapy
  • * Patient has not yet initiated Induction Cycle 3
  • * Patient aged 0-17 years at the time of consent
  • * Parent/guardian screened positive for self-reported low-income (\<200% Federal Poverty) \*
  • * Family primary residence in MA, PA, IL, CA, WA, CT, GA, WI and OH
  • * Both patients co-enrolled on ANBL2131 or those receiving standard of care therapy at their center are eligible to participate
  • * Patients of all languages are eligible to participate
  • * Foreign national family receiving care as an Embassy-pay patient.
  • * Child or household member receiving SSI

Ages Eligible for Study

to 17 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Dana-Farber Cancer Institute,

Kira Bona, MD, MPH, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

2029-06-01